Arie Belldegrun - May 24, 2021 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role: Director
Signature: /s/ Veer Bhavnagri, Attorney-in-Fact
Stock symbol: ALLO
Transactions as of: May 24, 2021
Transactions value $: $6,906,583
Form type: 4
Date filed: 5/25/2021, 08:00 AM
Previous filing: Jun 9, 2021
Next filing: Jun 9, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ALLO	Common Stock	Options Exercise	$6.91M	+379K	+185.85%	$18.22	583K	May 24, 2021	Direct
holding	ALLO	Common Stock						40K	May 24, 2021	See footnote	F1
holding	ALLO	Common Stock						1.8M	May 24, 2021	See footnote	F2
holding	ALLO	Common Stock						789K	May 24, 2021	See footnote	F3
holding	ALLO	Common Stock						3.71M	May 24, 2021	See footnote	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ALLO	Stock Option (Right to Buy)	Options Exercise	$0	-379K	-100%	$0.00^*	0	May 24, 2021	Common Stock	379K	$18.22	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The securities are held in the name of Bellco Legacy LLC (Bellco Legacy). Bellco Legacy is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun.
F2	The securities are held by Vida Ventures LLC (Vida), of which VV Manager LLC is the manager. The reporting person is a Senior Managing Director of VV Manager LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
F3	The securities are held in the name of Bellco Capital LLC, of which the reporting person is the manager.
F4	The securities are held in the name of the Belldegrun Family Trust.
F5	25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter.